A Systematic Evaluation of the Use of Physiologically Based Pharmacokinetic Modeling for Cross-Species Extrapolation

Autor: Thiel, Christoph, Schneckener, Sebastian, Krauss, Markus, Ghallab, Ahmed, Hofmann, Ute, Kanacher, Tobias, Zellmer, Sebastian, Gebhardt, Rolf, Hengstler, Jan G., Kuepfer, Lars ^*

Publikováno v: In Journal of Pharmaceutical Sciences January 2015 104(1):191-206

CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans

Autor: Chattopadhyay, Niladri, Kanacher, Tobias, Casjens, Manuela, Frechen, Sebastian, Ligges, Sandra, Zimmermann, Torsten, Rottmann, Antje, Ploeger, Bart, Höchel, Joachim, Schultze‐Mosgau, Marcus‐Hillert

AIMS: The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan. In addition, the effects of ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d300f5854905bb18eee57d4a460e33e4
https://europepmc.org/articles/PMC6256003/

The adenylyl cyclase cyaB1 from Anabaena sp. PCC 7120 is a cAMP-sensitive protein

Autor: Kanacher, Tobias

Das Gen CyaB1 aus dem Cyanobakterium Anabaena sp. PCC 7120 codiert für eine Adenylatcyclase, die aus zwei N-terminalen GAF-Domänen (GAF-A und GAF-B), einer PAS-Domäne, einer Klasse-IIIb-AC katalytischen Domäne und einer TPR-ähnlichen Domäne bes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______707::55178f9e01d8ba5921a3e14e0a78a909
https://hdl.handle.net/10900/48466

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.

Autor: Chattopadhyay N; Bayer AG, Berlin, Germany., Kanacher T; Bayer AG, Berlin, Germany., Casjens M; CRS Clinical Research Services Berlin GmbH, Berlin, Germany., Frechen S; Bayer AG, Berlin, Germany., Ligges S; Bayer AG, Berlin, Germany., Zimmermann T; Bayer AG, Berlin, Germany., Rottmann A; Bayer AG, Berlin, Germany., Ploeger B; Bayer AG, Berlin, Germany., Höchel J; Bayer AG, Berlin, Germany., Schultze-Mosgau MH; Bayer AG, Berlin, Germany.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2018 Dec; Vol. 84 (12), pp. 2857-2866. Date of Electronic Publication: 2018 Oct 11.